Rojkjaer Lisa 4

What Happened
Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals (RIGL), was granted 18,894 restricted stock units (RSUs) on February 17, 2026. The Form 4 reports the acquisition price as $0.00 (transaction code A), so no cash changed hands at grant. The RSUs will convert to common stock as they vest.

Key Details

• Transaction date: 2026-02-17; Form 4 filed 2026-02-19 (timely filing).
• Transaction type/code: Award/Grant (A).
• Shares awarded: 18,894 RSUs; reported acquisition price $0.00; reported total $0.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote (F1): RSUs vest quarterly over three years, with the first quarterly vesting on March 31, 2026.

Context
This was a compensation grant rather than an open-market purchase or sale. RSU awards are common executive compensation and do not result in issued shares until they vest; they therefore do not necessarily indicate immediate insider sentiment about the stock.